Duality Biotherapeutics Makes Hong Kong IPO Debut with ADC Pipeline
China-based Duality Biotherapeutics, Inc. (HKG: 9606) successfully debuted in Hong Kong after completing an initial...
Santen’s Tapcom Approved by China’s NMPA for Glaucoma Treatment
Japan-based Santen Pharmaceutical Co., Ltd. announced that it has received marketing approval from China’s National...
Peijia Medical’s ReachTactile Robot Assists First Human TAVR Trial
China’s Peijia Medical Ltd (HKG: 9996) has announced the successful treatment of the first patient...
Enhertu Approved by EC for Earlier-Line Treatment of HR+/HER2-low Breast Cancer
Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced that they have received approval...
Sino Biopharmaceutical’s TQB2101 Receives NMPA Approval for Phase I Trial in Advanced Malignancies
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received approval from the National...
Hengrui Pharmaceuticals Gains NMPA Approval for HRS-6719 in Solid Tumors
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical trial...
Sanofi’s Rilzabrutinib Granted Orphan Drug Designation for Rare Diseases
Sanofi (EPA: SAN, NASDAQ: SNY) announced that it has received Orphan Drug Designation (ODD) from...
Sunshine Guojian’s SSGJ-627 Gains NMPA Approval for Ulcerative Colitis Trial
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, (SHA: 688336) a subsidiary of 3SBio Inc. (HKG:...
Sarepta and Roche Seek to Resume Elevidys Trials After EMA Halt
The European Medicines Agency (EMA) may lift the temporary hold on certain Phase III studies...
Bayer’s Vividion Therapeutics Starts Phase I Study for RAS-PI3Kα Inhibitor
German pharmaceutical giant Bayer’s (ETR: BAYN) wholly owned subsidiary Vividion Therapeutics, Inc. has announced the...
ABL Bio and GSK Partner on Neurodegenerative Disease Therapies with Grabody-B Platform
South Korea-based clinical-stage biotech ABL Bio Inc. (KOSDAQ: 298380) has entered into a licensing agreement...
BeiGene Halts Ociperlimab Clinical Program for Lung Cancer
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), the China-based oncology specialist formerly known as...
Eli Lilly Secures Global License for Sangamo’s STAC-BBB Gene Therapy Technology
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has entered into a licensing agreement...
MicroPort Endovascular’s Talos Stent Approved in Brazil for Aortic Dissection
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) announced that it has received marketing approval...
Fujian Kerui’s Generic Sirolimus Gel Approved by China’s NMPA
China-based Fujian Kerui Pharmaceutical Co., Ltd. announced that its generic version of Pfizer’s (NYSE: PFE)...
Johnson & Johnson Completes Acquisition of Intra-Cellular Therapies
US-based Johnson & Johnson (NYSE: JNJ) announced the completion of its acquisition of fellow American...
Yuewei Medtech Secures RMB100 Million in Series A++ Funding for Cardiac Device Development
Beijing Yuewei Medical Technology Co., Ltd, a medical device company specializing in coronary heart disease,...
Boehringer Ingelheim Reports 6.1% Sales Growth in 2024, Bolstered by Key Pharmaceuticals
Germany-based Boehringer Ingelheim released its 2024 financial report, recording group net sales of EUR 26.8...
GE Healthcare Partners with Probo Medical to Distribute Ultrasound Devices
US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) has entered...
Henlius Biotech’s HLX04-O Shows Positive Results in wAMD Phase III Trial
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced positive results from the Phase III...